Article ; Online: Loss of Aurora Kinase Signaling Allows Lung Cancer Cells to Adopt Endoreplication and Form Polyploid Giant Cancer Cells That Resist Antimitotic Drugs.
2020 Volume 81, Issue 2, Page(s) 400–413
Abstract: Polyploid giant cancer cells (PGCC) are common in tumors and have been associated with resistance to cancer therapy, tumor relapse, malignancy, immunosuppression, metastasis, cancer stem cell production, and modulation of the tumor microenvironment. ... ...
Abstract | Polyploid giant cancer cells (PGCC) are common in tumors and have been associated with resistance to cancer therapy, tumor relapse, malignancy, immunosuppression, metastasis, cancer stem cell production, and modulation of the tumor microenvironment. However, the molecular mechanisms that cause these cells to form are not yet known. In this study, we discover that Aurora kinases are synergistic determinants of a switch from the proliferative cell cycle to polyploid growth and multinucleation in lung cancer cell lines. When Aurora kinases were inhibited together, lung cancer cells uniformly grew into multinucleated PGCCs. These cells adopted an endoreplication in which the genome replicates, mitosis is omitted, and cells grow in size. Consequently, such cells continued to safely grow in the presence of antimitotic agents. These PGCC re-entered the proliferative cell cycle and grew in cell number when treatment was terminated. Thus, PGCC formation might represent a fundamental cellular response to Aurora kinase inhibitors and contributes to therapy resistance or tumor relapse. SIGNIFICANCE: These findings provide a novel insight about how cancer cells respond to Aurora kinase inhibitors and identify a new mechanism responsible for resistance to these agents and other antimitotic drugs. |
---|---|
MeSH term(s) | Antimitotic Agents/pharmacology ; Apoptosis ; Aurora Kinase A/antagonists & inhibitors ; Aurora Kinase A/genetics ; Aurora Kinase A/metabolism ; Aurora Kinase B/antagonists & inhibitors ; Aurora Kinase B/genetics ; Aurora Kinase B/metabolism ; Biomarkers, Tumor/genetics ; Biomarkers, Tumor/metabolism ; Cell Proliferation ; Drug Resistance, Neoplasm ; Endoreduplication ; Gene Expression Regulation, Neoplastic ; Giant Cells/drug effects ; Giant Cells/metabolism ; Giant Cells/pathology ; Humans ; Lung Neoplasms/drug therapy ; Lung Neoplasms/metabolism ; Lung Neoplasms/pathology ; Neoplastic Stem Cells/drug effects ; Neoplastic Stem Cells/metabolism ; Neoplastic Stem Cells/pathology ; Tumor Cells, Cultured ; Tumor Microenvironment |
Chemical Substances | Antimitotic Agents ; Biomarkers, Tumor ; AURKA protein, human (EC 2.7.11.1) ; AURKB protein, human (EC 2.7.11.1) ; Aurora Kinase A (EC 2.7.11.1) ; Aurora Kinase B (EC 2.7.11.1) |
Language | English |
Publishing date | 2020-11-10 |
Publishing country | United States |
Document type | Journal Article ; Research Support, N.I.H., Extramural |
ZDB-ID | 1432-1 |
ISSN | 1538-7445 ; 0008-5472 |
ISSN (online) | 1538-7445 |
ISSN | 0008-5472 |
DOI | 10.1158/0008-5472.CAN-20-1693 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Uh III Zs.135/5: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.